Description: Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
Home Page: www.bettertx.com
BTTX Technical Analysis
548 Market Street
San Francisco,
CA
94104
United States
Phone:
415-887-2311
Officers
| Name | Title |
|---|---|
| Mr. David P. Perry M.B.A. | Co-Founder & Exec. Chairman |
| Dr. Mark A. Berman M.D. | Chief Medical Officer |
| Ms. Kristin Wynholds | Chief Product Officer |
| Mr. Frank L. Karbe | CEO, Pres & Director |
| Mr. Mark Heinen | Head of Fin. & Interim CFO |
| Mr. Andres Camacho | Sr. VP of Technology & Head of Engineering |
| Mr. Thiago Licias De Oliveira | Chief People Officer |
| Ms. Diane Gomez-Thinnes | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5838 |
| Price-to-Sales TTM: | 49559.4078 |
| IPO Date: | 2021-10-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |